Summary
Eric Alton is Professor of Gene Therapy and Respiratory Medicine, National Heart & Lung Institute, Imperial College London and Honorary Consultant Physician, Royal Brompton Hospital
Professor Alton was educated at Jesus College, Cambridge and Westminster Medical School and subsequently undertook six years of general medical training. Over the last fifteen years, he has been involved in developing gene therapy for cystic fibrosis and angiogenesis, including three clinical trials.
Professor Alton coordinates the UK CF Gene Therapy Consortium which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College), including approximately 80 clinicians and scientists focused on this problem.
Publications
Journals
Alton E, Lund-Palau H, Juarez-Molina C, et al., 2022, Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression, Molecular Therapy - Methods and Clinical Development, ISSN:2329-0501
Balachandar S, Graves TJ, Shimonty A, et al., 2022, Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations, American Journal of Medical Genetics Part A, Vol:188, ISSN:0148-7299, Pages:959-964
Edmondson C, Westrupp N, Seddon P, et al., 2022, The feasibility of home monitoring of young people with cystic fibrosis: results from CLIMB-CF, Journal of Cystic Fibrosis, Vol:21, ISSN:1569-1993, Pages:70-77
Conference
Bell R, Faulkner N, Griesenbach U, et al., Intravenous administration of F/HN pseudotyped lentiviral vector, ESGCT Collaborative Virtual Congress, Mary Ann Liebert, ISSN:1043-0342
Bell RV, Isalan M, Alton EWFW, et al., Regulation of lentivirus‐mediated expression in a human airway model, ESGCT Collaborative Virtual Congress, Mary Ann Liebert, ISSN:1043-0342